1. McKinsey. Biosimilars seven years on: where are we and what’s next?
https://www.mckinsey.com/~/media/mckinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/Biosimilars%20Seven%20years%20on_White%20Paper.ashx
(2013).
2. Gross, H. J. & Vietri, F. Barriers to Biologic Therapy Use for Autoimmune Disorders in Emerging Markets, International Society for Pharmacoeconomics and Outcomes Research: 16th Annual European Conference (2013).
3. Ghosh, A., Ray, S., Dewan, S., Shah, K. & Sahani, K. Indian Pharmaceutical Sector (ICRA Ltd., New Delhi, 2012).
4. Pharmaceutical Export Promotion Council of India. 11th Annual Report, 2014–2015 (Government of India, Bangalore, India, 2015).
5. Edney, A. & Mittelman, M. Valeant, Turing would face subpoena vote under Democrat’s plan. Bloomberg
http://www.bloomberg.com/news/articles/2015-11-04/valeant-turing-would-face-subpoena-vote-under-democrats-plan
(4 November 2015).